RE
IOVA icon

RBC Europe’s Iovance Biotherapeutics IOVA Stock Holding History

RBC Europe’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-295
Closed -$13.7K – 1213
2020
Q4 		$13.7K Hold
295
– – ﹤0.01% 818
2020
Q3 		$9.71K Hold
295
– – ﹤0.01% 805
2020
Q2 		$8.1K Sell
295
-7,155
-96% -$235K ﹤0.01% 804
2020
Q1 		$223K Sell
7,450
-5,370
-42% -$142K 0.02% 196
2019
Q4 		$355K Buy
12,820
+7,665
+149% +$174K 0.03% 190
2019
Q3 		$93.8K Sell
5,155
-2,120
-29% -$46.9K 0.01% 345
2019
Q2 		$178K Buy
7,275
+2,120
+41% +$31.9K 0.02% 260
2019
Q1 		$49K Hold
5,155
– – 0.01% 460
2018
Q4 		$45.6K Hold
5,155
– – 0.01% 458
2018
Q3 		$58K Hold
5,155
– – 0.01% 448
2018
Q2 		$66K Buy
+5,155
New +$75.3K 0.01% 415

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

RBC Europe's IOVA Position: Q1 2021 in Review

RBC Europe sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 295 shares — an estimated $13.7K sold.

RBC Europe first reported a position in IOVA in Q2 2018 and held it in 11 quarters. The position peaked at $355K in Q4 2019. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • RBC Europe reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 295 Iovance Biotherapeutics shares in Q1 2021, an estimated $13.7K.
  • RBC Europe first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 11 quarters.
  • RBC Europe's Iovance Biotherapeutics position peaked at $355K in Q4 2019.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.